Clinical trialsCompany release

Pyxis Oncology reports 39% confirmed response rate for micvotabart pelidotin in head and neck cancer

🇺🇸 Pyxis Oncology, Inc. (PYXS) · Thu 19 Nov 2026

Updated Phase 1 data for the antibody-drug conjugate in second-line-plus recurrent or metastatic HNSCC show a median response duration of 9.2 months, with a Phase 3 planned for mid-2027.

Pyxis Oncology has released updated Phase 1 monotherapy results for its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with second-line-plus recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data cutoff was 14 October 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Pyxis Oncology, Inc. ↗

Article written by VigiEye from the official source (Pyxis Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.